I am currently part of the 'Cannabinoids Signaling in Tumor Cells' lab, led by Professors Guillermo Velasco and Mar Lorente. Here, I work closely with the entire team, contributing to advancing our understanding of cannabinoid effects on cancer biology.

Dr. Donadelli is a Full Professor of Biochemistry and leads a research group at the University of Verona. He was my PhD supervisor from 2014 to 2016 and currently remains one of my strongest supporters and a key collaborator, particularly in the field of mutant p53 biology in cancer.

Dr. Somoza is Senior Research Professor at Fundación IMDEA Nanociencia and he mentored me during my postdoctoral period from 2018 to 2020. Under his guidance, I developed a profound interest in the application of nanomedicine for cancer therapy—an area I continue to explore with great passion. We have great idea to further collaborate on significant projects focused on developing stimulus-responsive nanomaterials for targeted drug delivery of nucleic acids to counteract GOF mutant p53 proteins.

Dr. Strippoli is an Associate Professor at "La Sapienza" University of Rome and a pioneering expert in the EMT process across diseases and physiology. Over the past years, we have collaborated on various studies focused on understanding the molecular interplay between autophagy and EMT. Our collaboration extends to active editorial roles and ongoing interactions. Moreover, he is my great friend from whom I have received invaluable mentorship and motivational support during challenging times that I encountered across my path.

Dr. Zarrabi is Associate Professor at Instinye University, renowned for his expertise in nanomaterials, nanotheranostics, novel wound dressings, skin patches, and translational nanomedicine. We maintain a close and productive collaboration across various aspects of nanomedicine, particularly in developing and evaluating niosome and polymeric nanomaterials for drug delivery and combined therapies in cellular models. Our collaboration extends to joint editorial responsibilities in several prestigious journals, underpinned by a friendly and professional interaction.

Dr. Ghavami is Associate Professor at the University of Manitoba, is renowned for his contributions to the study of autophagy and stress-related signaling pathways. He is not only a highly respected scientist but also a mentor who exemplifies dedication, sacrifice, and perseverance. His journey to success is compellingly detailed in his book, 'Road to Human Flourishing: How to Ignite Your Health, Wealth, and Success.' Our collaborative efforts range from editorial responsibilities to co-authoring research articles, all aimed at advancing our understanding of autophagy and mitophagy in cancer models. 

Dr. Rizzolio is Full Professor at University of Venice and at "CRO" Oncology Center, Aviano. He is a highly esteemed scientist and professor who provided notable contributions in the field of cancer research. Togheter with his team, he is deeply committed to identifying novel therapeutic opportunities for ovarian and colon cancer patients using patient-derived cancer organoids and other cutting-edge technologies. They are also dedicated to developing advanced smart nanomaterials with intrinsic therapeutic properties. Our collaboration emerged from our shared interest in the therapeutic applications of nanomaterials in cancer treatment. Together, we are exploring exciting opportunities to jointly discover anticancer drugs that target specific cancer biomarkers.

Dr. Moosavi is Associate Professor and Vice President for Research at NIGEB, Iran, leads research focused on understanding the molecular mechanisms regulating the interaction between autophagy and the unfolded protein response (UPR), alongside developing systems biology approaches. Our recent collaboration has been both intense and fruitful, concentrating on characterizing novel regulated cell death mechanisms following nanomaterials treatment and identifying peptides and drugs that target autophagy proteins. Leveraging drug repurposing strategies and bioinformatic technologies, we aim to expand our research to include the identification of small molecules that target GOF mutant p53 and reactivate the WT p53 form.

Professor Mori was my classmate during our university years and has remained a long-time friend. Now an Assistant Professor at the University of Parma, she teaches Bioinformatics and investigates the co-evolution of genes involved in metabolic pathways. Leveraging her expertise, we recently initiated a collaboration in the field of Bioinformatics to study GOF mutant p53 proteins in cancer. Specifically, she plays a crucial role in helping me interpret databases and OMICs data.

Professor Dando and her team are dedicated to understanding the key metabolic characteristics of cancer stem cells and dissecting the molecular mechanisms that affect fertility potential in patients with andrological pathologies. An old friend from my doctoral studies, we have recently intensified our collaboration through editorial projects and research focusing on the molecular and metabolic aspects of male-related cancers.

Professor Tafani is an Associate Professor at the University of Rome and an expert in Sirtuin biology, with a focus on both physiology and disease as well as on therapeutic targeting in cancer using nanoparticles. We have recently intensified our collaboration, particularly planning to explore the role of post-translational modifications in mutant p53 and the mechanisms regulating its degradation.

She is Chief Scientist at Centre for Cellular & Molecular Biology (CSIR), India. Her research focuses on developing therapeutic strategies targeting the Wnt pathway and EMT, which are crucial in cancer progression, and on identifying novel non-coding RNAs as biomarkers in breast cancer. Our collaboration consists in various projects aimed at elucidating the roles of miRNAs and lncRNAs in EMT, as well as developing therapeutic strategies to counteract their effects